Published in Pharma Law Weekly, January 12th, 2004
In exchange, Mentor will pay WARF a royalty on sales of botulinum toxin products in addition to cash payments at certain milestones in the regulatory approval process.
The University of Wisconsin-Madison has been the pioneer in the development of botulinum toxins for over 30 years. The University has developed intellectual property that includes the composition,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.